CTLA-4 is one of the first immune checkpoints to be clinically targeted in cancer therapy and Ipilimumab (Bristol–Myers Squibb, New York, NY, USA), a monoclonal CTLA-4 antibody, was approved by FDA in 2011 for the treatment of metastatic melanoma [68]. This evidence concerns the gene CTLA4 and cancer.